mounjaro patent expiration tirzepatide patent expiry These highlights do not include

GLP-1 medications have demonstrated significant weight loss outcomes in clinical trials of FDA-approved branded products, and telehealth platforms have emerged to provide access to compounded versions of these medications at various price points

It is meant to be used in combination with diet and exercise

Tirzepatide has a lower rate of nausea and vomiting compared to Semaglutide, likely due to the presence of GIP, which helps mitigate gastrointestinal discomfort

Tirzepatide, marketed as Mounjaro, is quickly becoming one of the most talked-about medications in the fight against stubborn weight gain

Appetite reduction is common